Researchers challenge genetic tests for guiding psychiatric treatment

May 23, 2018, McLean Hospital

In a paper published in JAMA Psychiatry, McLean Hospital's Program for Neuropsychiatric Research director Bruce M. Cohen, MD, Ph.D., and his colleagues, George S. Zubenko, MD, Ph.D., University of Pittsburgh School of Medicine (retired), and Barbara R.M. Sommer, MD, Stanford University School of Medicine, emerita, reviewed the scientific basis and effectiveness of pharmacogenetic (Pgen) tests in guiding the choices and doses of psychiatric medications for treating major depressive disorder (MDD) and related psychiatric conditions.

The , "On the Marketing and Use of Pharmacogenetic Tests for Psychiatric Treatment," comes at a time when a growing industry is vigorously marketing Pgen tests by claiming their results can improve the outcomes of patients with . According to the paper, one company website reported having already sold over 650,000 Pgen tests, with an estimated cost of $1 billion in genotyping and related clinical services.

As noted by Zubenko, the first author of the paper, "While the promise of Pgen-guided medication treatment of psychiatric disorders is appealing and supports the popular narrative of personalized/precision medicine, available evidence suggests that Pgen testing will not contribute much to improving care, if at all. And, in some cases, it could provide misleading information."

Citing the genomic evidence on psychiatric disorders, including MDD, the researchers raised questions about the likelihood that Pgen tests would predict either MDD or how patients will respond to treatment. This assessment arises from the very nature of the condition. As described in the paper, MDD is determined by a very large number of genes, and no single gene or limited gene set, even those for drug metabolism and drug targets, determine more than a few percent of the risk of illness or course of treatment, except in rare cases. Rather than genes, demographic and environmental factors, general health, clinical characteristics (psychiatric symptoms, severity, and comorbidity), and co-medication are usually much more important factors than inherited determinants of drug metabolism and response.

Moreover, the paper noted that while the activity of metabolic enzymes is heritable, extremely rapid or slow metabolism is rare, and dosing should be guided by careful dose choice and monitoring therapeutic and side effects rather than by Pgen results. As for medication choice, the authors pointed out that there are standard evidence-based protocols to assist in clinical decision making.

The authors described multiple significant flaws in the design, implementation, and analysis of the 10 published effectiveness studies. Most studies evaluated by the authors were neither controlled nor blinded, and not a single paper was adequately blinded and properly controlled. In addition, the studies cited in marketing and promotional materials were funded by and included co-authors from the companies that offer Pgen services.

According to the authors, well-designed, controlled, and fully blinded studies are needed to determine whether expensive Pgen-guided care outperforms good care performed by board-certified psychiatrists using published protocols for the treatment of MDD. Efforts should also be made, they said, to minimize or eliminate financial and other conflicts of interest that may arise in the conduct of the studies and analysis of the results.

Zubenko emphasized that "doctors, patients, and family members should understand that the jury is out on whether Pgen testing improves good psychiatric care performed by board-certified psychiatrists." He further observed that "in a time of strained mental health care budgets, it's worth asking whether these federal and private healthcare dollars could be better spent on proven methods of care for patients with mental illnesses."

Cohen noted that "new technologies, when properly tested, should become part of clinical assessment, but Pgen has not passed such tests." He warned that "similar studies of inadequate design only add to the number of Pgen tests performed, not to the quality of the evidence on the value of those tests, and clinicians should be cautious in accepting claims until appropriate studies are performed."

Explore further: Study shows family psychiatric history increases risk of postpartum psychiatric episodes

Related Stories

Study shows family psychiatric history increases risk of postpartum psychiatric episodes

May 7, 2018
A new mother's risk of postpartum psychiatric conditions increases when she has an immediate family member with a psychiatric disorder, especially bipolar disorder, according to research published today in the American Journal ...

Asthma and hay fever linked to increased risk of psychiatric disorders

April 23, 2018
Patients with asthma and hay fever have an increased risk of developing psychiatric disorders, finds a new study published in open-access journal Frontiers in Psychiatry. Almost 11% of patients with common allergic diseases ...

New study launched investigating the impacts of personal genomic testing

March 5, 2012
As genetic risk information plays an increasingly important role in the diagnosis and treatment of many diseases, private companies have made personal genomic testing for these risk factors widely available to the public. ...

Cognitive remediation can be implemented in large systems of psychiatric care

May 3, 2018
Cognitive remediation, an evidence-based, recovery-oriented behavioral intervention for patients with mental illness, can feasibly be implemented in large systems of care, according to researchers at the New York State Psychiatric ...

Studies probe value and impact of direct-to-consumer genetic testing

December 13, 2016
Despite being on the market for nearly a decade, direct-to-consumer (DTC) genetic testing continues to be controversial among experts and raises concerns among health care providers and regulatory agencies. The NIH-funded ...

New method extracts information on psychiatric symptoms from electronic health records

February 26, 2018
Researchers at Massachusetts General Hospital and Harvard Medical School have developed a new method to extract valuable symptom information from doctors' notes, allowing them to capture the complexity of psychiatric disorders ...

Recommended for you

Psychiatric disorders share an underlying genetic basis

June 21, 2018
Psychiatric disorders such as schizophrenia and bipolar disorder often run in families. In a new international collaboration, researchers explored the genetic connections between these and other disorders of the brain at ...

One year of school comes with an IQ bump, meta-analysis shows

June 21, 2018
A year of schooling leaves students with new knowledge, and it also equates with a small but noticeable increase to students' IQ, according to a systematic meta-analysis published in Psychological Science, a journal of the ...

Ketamine acts fast to treat depression and its effects last—but how?

June 21, 2018
In contrast to most antidepressant medications, which can take several weeks to reduce depressive symptoms, ketamine—a commonly used veterinary anesthetic—can lift a person out of a deep depression within minutes of its ...

Mindful movement may help lower stress, anxiety

June 21, 2018
Taking a walk may be a good opportunity to mentally review your to-do list, but using the time to instead be more mindful of your breathing and surroundings may help boost your wellbeing, according to researchers.

Brain tingles—first study of its kind reveals physiological benefits of ASMR

June 21, 2018
Autonomous sensory meridian response (ASMR) – the relaxing 'brain tingles' experienced by some people in response to specific triggers, such as whispering, tapping and slow hand movements – may have benefits for both ...

New study debunks Dale Carnegie advice to 'put yourself in their shoes'

June 21, 2018
Putting yourself in someone else's shoes and relying on intuition or "gut instinct" isn't an accurate way to determine what they're thinking or feeling," say researchers from Ben-Gurion University of the Negev (BGU), the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.